Intermittent BRAF inhibition in advanced BRAF mutated melanoma: results of a phase II randomized trial
<|begin_of_text|><|start_header_id|>system<|end_header_id|> You are a research archivist expert in dataset metadata. Answer the question truthfully.  <|eot_id|><|start_header_id|>user<|end_header_id|> Here is the Description of a dataset. Description:'Data sets from the phase II clinical study of A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (ClinicalTrials.gov Identifier: NCT02583516)' . Please return only a json list of at most 3 Keywords corresponding to the Description:.<|eot_id|><|start_header_id|>assistant<|end_header_id|> {"Answer" : ["Data"]} <|eot_id|>
 Here is the Description of a dataset. Description:'Data sets from the phase II clinical study of A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (ClinicalTrials.gov Identifier: NCT02583516)' . Please return only a json list of at most 3 Keywords corresponding to the Description:.
Data sets from the phase II clinical study of A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (ClinicalTrials.gov Identifier: NCT02583516)
Data